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B cells can use antibody-dependent mechanisms to control latent viral infections. It is unknown whether this
represents the sole function of B cells during chronic viral infection. We report here that hen egg lysozyme (HEL)-
specific B cells can contribute to the control of murine c-herpesvirus 68 (cHV68) latency without producing anti-viral
antibody. HEL-specific B cells normalized defects in T cell numbers and proliferation observed in B cell / mice during
the early phase of cHV68 latency. HEL-specific B cells also reversed defects in CD8 and CD4 T cell cytokine production
observed in B cell / mice, generating CD8 and CD4 T cells necessary for control of latency. Furthermore, HEL-specific
B cells were able to present virally encoded antigen to CD8 T cells. Therefore, B cells have antibody independent
functions, including antigen presentation, that are important for control of c-herpesvirus latency. Exploitation of this
property of B cells may allow enhanced vaccine responses to chronic virus infection.
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Introduction
c-Herpesviruses such as Epstein Barr virus (EBV), Kaposi’s
sarcoma herpesvirus (KSHV), and murine c–herpesvirus 68
(cHV68) latently infect lymphocytes and other cells as part of
a strategy for maintaining life-long infection. Latent in-
fection represents a balance between the virus and the host to
which immunity makes an essential contribution. c-herpesvi-
rus latency and replication of virus that has reactivated from
latently infected cells contribute to c-herpesvirus-associated
diseases [1–7]. The stability of this balance between virus and
host is demonstrated by the observation in mice that a latency
‘‘set point’’ exists such that the same number of cells are
latently infected regardless of the dose or route of infection
[8], and in humans by the observation that individuals have a
stable level of EBV latency over years [9]. Despite the stability
of c-herpesvirus latency, the balance between virus and host
is delicate since c-herpesvirus-induced disease is most often
seen in immunocompromised hosts. In addition, deletion of
individual host [7,10,11] or viral [12–14] genes disrupts this
balance with consequent inefﬁcient infection or development
of disease.
To understand the stable but delicate balance between the
host and c-herpesviruses present during life-long infection, it
is necessary to deﬁne mechanisms of immunity responsible
for holding the virus at bay. To deﬁne these mechanisms
many groups have studied infection of mice with cHV68,
which provides a relevant small animal model for c-
herpesvirus infection and immunity. After clearance of acute
infection, cHV68 latently infects macrophages, B cells, and
dendritic cells [8,15–18]. cHV68 infection is associated with
development of B cell malignancies, vasculitis, and athero-
sclerosis [2,7,19,20].
Immunity controls latent cHV68 infection by limiting the
number of cells carrying viral genome during latency
[10,21,22] and by regulating the efﬁciency with which these
cells reactivate from latency when explanted [10,11,23,24]. In
addition, the immune system regulates persistent viral
replication, which is detected as the presence of preformed
infectious virus in tissues after clearance of the acute
infection [7,10,11,17,23]. Persistent cHV68 replication is
distinct from replication occurring during acute infection
(acute replication) since the cHV68 v-cyclin and v-Bcl-2 genes
are required for persistent but not acute replication [12–14].
Persistent replication is observed in normal mice, and is more
prominent in immunocompromised mice such as those
lacking B cells or interferon-c (IFNc) [7,10,14,17,23]. It is
likely that persistent replication involves virus that has
reactivated from latently infected cells since the v-cyclin
and v-Bcl-2 genes are required for both efﬁcient reactivation
from latency and for persistent replication [12,13]. Persistent
replication may contribute to latency via infection of new
cells that enter the latent pool [25,26].
There are two forms of cHV68 latency that are distinguish-
able experimentally [8,10–12]. The early form of latency is
measurable 16 d after infection when acute infection has
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genome reactivate when cultured ex vivo [11]. The late form
of latency, typically measured at 42 d after infection, is
characterized by inefﬁcient reactivation ex vivo with 10% or
less of genome bearing cells reactivating when explanted
[10,11]. Latency is typically measured in the spleen as a
lymphoid site and the peritoneum as a body cavity site.
Analysis of these sites is of interest since both EBV and KSHV
establish latency in lymphoid sites and KSHV causes body
cavity based lymphomas [3–5]. Both the early and late forms
of latency in splenocytes and peritoneal cells are observed
regardless of the route (intraperitoneal or intranasal) or dose
of viral inoculation [8].
Several components of the immune system contribute to
the control of latent and persistent cHV68 infection. These
include CD8 T cells [10,21,22], CD4 T cells [21,27–29],
perforin [10], granzymes [30], caspase 3 [30], IFNc
[6,7,10,24,29], IFNab [23], and antibody and B cells
[11,25,26]. Of these, the role of B cells is of particular interest
because c-herpesviruses including EBV, KSHV, and cHV68
establish latency in B cells. In addition to serving as a site of
latent infection, B cells regulate latency in non-B cells [11]. B
cell / mice exhibit increased frequencies of reactivating and
viral genome bearing cells compared to B6 mice [11], and
show increased persistent replication in lung and aorta
[6,7,14,31]. Thus, removal of one latent reservoir, B cells,
increases the level of latency in non-B cells, and diminishes
control of persistent replication. Lack of speciﬁc anti-viral
antibody likely explains some of the abnormalities in latency
and persistence seen in B cell /  mice. Passive transfer of
antibody signiﬁcantly decreases the frequency of latently
infected cells in B cell /  or T cell depleted CD28 /  mice
[25,26]. However, it is not known whether the important role
of B cells in control of cHV68 latency and persistent
replication is explained by production of anti-viral antibody
or other antigen-speciﬁc B cell receptor (BCR)-dependent
activities of B cells.
To identify B cell activities during infection that are
independent of antibody production and expression of a
virus antigen-speciﬁc BCR we bred a mouse that contained B
cells but cannot mount an antigen speciﬁc anti-viral B cell
response (HELMET mice). We found that the abnormal
control of latency in B cell / mice was largely normalized by
the presence of viral antigen non-speciﬁc B cells. Further-
more, abnormalities in CD8 and CD4 T cell expansion and
IFNc production observed in B cell / mice were reversed in
HELMET mice. Depletion of either T cell subset resulted in
increased latent infection in HELMET mice but had minimal
effects in B cell /  mice. B cells therefore have critically
important antibody- and antigen-speciﬁc BCR-independent
functions during chronic cHV68 infection that are at least in
part explained by B cell-dependent induction of CD8 and
CD4 T cell responses.
Results
HEL-Specific B Cells Decrease the Frequency of
Splenocytes That Reactivate from Latency and Decrease
the Efficiency of Reactivation from Latency
B cell / mice have higher numbers of cells carrying latent
cHV68 than wild type mice [11]. We wanted to determine
whether the effects of B cells on latent cHV68 infection
require production of anti-viral antibody and engagement of
a virus antigen-speciﬁc BCR. One approach to this question
would be to study the effects of adoptively transferred B cells
on cHV68 infection of B cell /  mice. However, adoptively
transferred B cells do not persist in this setting [32,33],
necessitating a genetic approach to engrafting virus antigen
non-speciﬁc mice onto a B cell /  background. We therefore
bred the HEL-speciﬁc IgM/IgD BCR bearing the IgM
a allotype
from MD4 mice [34] onto the lMT B cell /  background [35]
(Figure 1, HELMET mice). HELMET mice contained IgM
a and
CD19 double positive B cells in spleen (Figure 1) and lymph
nodes (unpublished data) while B6 mice and B cell /  mice
did not.
To determine if HEL-speciﬁc B cells can control the late
form of latency in a lymphoid site we examined splenic
latency in B6, HELMET, and B cell /  mice (Figure 2). We
conﬁrmed a prior report [11] that the frequency of
splenocytes from B cell /  mice that reactivate from latency
ex vivo is signiﬁcantly elevated compared to the frequency
observed in splenocytes from B6 mice (p ¼ 0.003, Figure 2A).
The frequency of splenocytes from HELMET mice that
reactivated ex vivo was indistinguishable from the frequency
observed in splenocytes from B6 mice and was signiﬁcantly
lower than that observed in splenocytes from B cell / mice (p
¼ 0.0001). Therefore, the presence of HEL-speciﬁc B cells
Figure 1. HELMET Mice Contain Transgenic B Cells
Splenocytes from naı ¨ve B6, HELMET, and B cell /  mice were stained
with antibodies against CD19 and IgM
a. Numbers represent percentages
of cells in the indicated quadrants.
DOI: 10.1371/journal.ppat.0020058.g001
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Virus Non-Specific B Cells Limit Latency
Synopsis
B cells can control virus infection by making specific antibodies that
bind to virus and infected cells. However, it is unknown whether B
cells perform other anti-viral functions to protect the host during
infection. The authors addressed this question by infecting mice
with murine c-herpesvirus 68 (cHV68), a relative of Epstein-Barr virus
and Kaposi’s sarcoma associated virus, which establishes lifelong
latent infection in mice. Mice lacking B cells (B cell / ) failed to
control latent cHV68 infection and had reduced T cell activity
compared to wild-type mice. In order to determine if virus non-
specific B cells can control latency, the authors engineered mice that
contain B cells, but cannot generate antibodies that bind to cHV68.
Virus non-specific B cells restored normal control of latency and T
cell activation defects observed in B cell / mice, and could present
virus-encoded antigen to T cells. Thus, B cells can play a critical role
in control of chronic viral infection independent of their capacity to
make anti-viral antibody. Defining the mechanisms for this unique
activity of B cells may provide novel ways to treat or control chronic
viral infection.normalized defects in the control of splenic latency observed
in B cell /  mice.
We next determined whether effects of HEL-speciﬁc B cells
on splenic latency were due to alterations in the frequency of
viral genome bearing cells or in the efﬁciency of reactivation
of explanted latently infected cells (deﬁned as the frequency
of cells reactivating ex vivo divided by the frequency of cells
bearing viral genome multiplied by 100). The frequencies of
genome positive splenocytes in B cell / , HELMET, and B6
mice were similar (Figure 2B, right panel). About 15% of viral
genome positive splenocytes from B cell /  mice reactivated
ex vivo compared to about 2% in B6 mice and 3% in
HELMET mice (Figures 2A and 2B, right panels). Therefore
the effects of HEL-speciﬁc B cells on splenic latency were due
to changes in the efﬁciency of ex vivo reactivation rather than
the frequency of cells bearing viral genome.
HEL-Specific B Cells Decrease the Frequency of Peritoneal
Cells That Reactivate from Latency and That Carry Latent
cHV68 Genome
To determine whether viral antigen non-speciﬁc B cells can
restore normal regulation of latency in a body cavity site we
compared the late form of latency in B6, HELMET, and B
cell /  mice. Consistent with previous results [11], the
frequency of reactivating cells in B cell /  mice was 200-fold
higher than in B6 mice (Figure 2A, left panel, p¼0.008). HEL-
speciﬁc B cells were able to decrease reactivation from
latency in peritoneal cells since the frequency of reactivating
cells was 20-fold less in HELMET mice in comparison to B
cell /  mice (p ¼ 0.0053). However, the frequency of
reactivating peritoneal cells in HELMET mice was 11-fold
higher than that in peritoneal cells from B6 mice (Figure 2A,
left panel, p ¼ 0.05). These data demonstrate that HEL-
speciﬁc B cells limit reactivation from latency in peritoneal
cells, but do not fully compensate for the presence of normal
B cells.
We next determined whether the decreased frequency of
peritoneal cells that reactivate from latency in HELMET mice
compared to B cell /  mice was due to a decrease in the
frequency of latently infected cells by measuring the
efﬁciency of reactivation. Consistent with published results
[11], the frequency of viral genome-positive cells was 10-fold
higher in peritoneal cells from B cell / mice than in B6 mice
(Figure 2B, left panel, p ¼ 0.01). Thus, roughly 100% of
latently infected peritoneal cells from B cell /  mice
reactivated from latency when explanted while only 6% of
latently infected peritoneal cells from B6 mice reactivated
(compare Figures 2A and 2B). HEL-speciﬁc B cells decreased
the frequency of cells carrying latent viral genome to levels
similar to those observed for B6 mice (p ¼ 0.36). However,
about 81% of viral genome bearing peritoneal cells from
HELMET mice reactivated when explanted. Thus the effect of
HEL-speciﬁc B cells on latency in peritoneal cells is largely via
decreasing the frequency of cells carrying latent viral
genome.
The Effects of HEL-Specific B Cells on cHV68 Latency Are
Not Due to Cross-Reactivity between HEL and cHV68
The data provided above show that the presence of HEL-
speciﬁc B cells has signiﬁcant effects on cHV68 latency in two
different sites. To determine whether these effects were virus-
speciﬁc antibody independent we needed to determine
whether anti-cHV68 antibody is generated in either B cell / 
or HELMET mice. To address this issue we used enzyme-
linked immunosorbent assay (ELISA), viral neutralization
assays, and passive transfer experiments (Figure 3).
As expected, anti-viral antibody was found by ELISA in
serum from infected B6 mice but not in serum from infected
B cell /  or HELMET mice (Figure 3A, left panel). Antibody
speciﬁc to HEL was detected in mock infected and cHV68
infected HELMET mice (unpublished data). Similarly, serum
from cHV68 infected B6 mice neutralized cHV68, while
serum from infected B cell /  or HELMET mice did not
(Figure 3A, right panel). Thus anti-HEL antibodies do not
cross-react with cHV68 in ELISA or neutralization assays and
infected B cell /  and HELMET mice fail to make detectable
antibody to cHV68.
To rule out the possibility that ELISA and neutralization
assays failed to detect physiologically relevant anti-cHV68
antibody in the serum of HELMET mice and that HEL
speciﬁc antibody in the serum of HELMET mice might alter
cHV68 latency, we compared the effect of passively trans-
ferred serum from infected HELMET or B6 mice on latency
in B cell /  mice. We and others previously demonstrated
that the passive transfer of anti-viral antibody can decrease
the number of latently infected cells [25] and decrease the
recrudescence of lytic virus [26] in latently infected mice by
blocking lytic viral replication [25]. The transfer of control
serum from either B6 or HELMET mice had no effect on
latency in B cell /  mice (compare Figures 2A and 3B). As
previously published [25], passively transferred immune
Figure 2. Virus Non-Specific B Cells Control Latent Infection
(A) Ex vivo reactivation from latency in peritoneal cells (left) and
splenocytes (right) from B6, HELMET, and B cell /  mice 42 d after
infection. Dotted lines indicate the 63.2% Poisson distribution line used
to calculate the frequency of cells reactivating virus.
(B) Frequency of cells from peritoneal cells (left) and splenocytes (right)
carrying cHV68 genome in B6, HELMET, and B cell / mice at day 42 post
infection. Dotted lines indicate the 63.2% Poisson distribution line used
to calculate the frequency of cells carrying viral genome. As indicated in
the Materials and Methods section, results from 10–15 total mice from
two to three independent experiments 6 SEM are reported here.
DOI: 10.1371/journal.ppat.0020058.g002
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Virus Non-Specific B Cells Limit Latencyserum from cHV68 infected B6 mice decreased the frequency
of peritoneal cells reactivating from latency more than 100-
fold compared to the transfer of control serum from mock
infected B6 mice (Figure 3B, p ¼ 0.05), and of splenocytes
more than 4-fold (Figure 3B, p ¼ 0.01). In contrast, serum
from infected HELMET mice had no effect on latency (Figure
3B).
Together these data show that there is no cHV68-reactive-
antibody in infected HELMET mice and that HEL-speciﬁc
antibody in serum of HELMET mice did not alter cHV68
latency. We conclude that the control of latency observed in
HELMET mice (Figures 2A and 2B) is dependent on the
presence of HEL-speciﬁc B cells rather than antibody or a
virus antigen-speciﬁc BCR.
Effects of HEL-Specific B Cells on Latency Are Not
Explained by Decreases in Acute cHV68 Replication
The above data showed that B cells that do not produce
anti-viral antibody or express a virus antigen-speciﬁc BCR
can nevertheless have signiﬁcant effects on latent cHV68
infection. To deﬁne the mechanism responsible for this effect
we ﬁrst determined whether effects of HEL-speciﬁc B cells on
acute cHV68 replication might explain decreases in cHV68
latency detected in HELMET mice. We therefore measured
cHV68 replication in B6, HELMET, and B cell /  mice 4 and
9 d after infection. 4 d after infection, viral titers were similar
in B6, HELMET, and B cell / mice (p . 0.2, Figure 4). On day
9, cHV68 titers were more than 100-fold greater in B6 mice (p
, 0.0001) than in B cell /  mice (Figure 4), reﬂecting the
importance of B cells for maintaining cHV68 replication [36].
The presence of HEL-speciﬁc B cells led to increased cHV68
replication compared to B cell / mice (p , 0.0001) 9 d after
infection, but did not fully normalize splenic titers (p ,
0.0001). These data show that decreased latency in HELMET
mice compared to B cell /  mice cannot be explained by
decreased cHV68 replication in HELMET mice.
HEL-Specific B Cells Correct Abnormalities in Splenocyte
Numbers Observed in B cell /  Mice
Based on studies in other systems comparing responses to
infection in the presence and absence of B cells [33,37–40], we
reasoned that increases in T cell responses in the presence of
HEL-speciﬁc B cells might contribute to control of cHV68
latency. We therefore determined whether HEL-speciﬁc B
cells restore abnormalities in splenic cellularity that have
been reported in B cell /  mice including reduced numbers
of splenocytes, CD8 T cells, and CD4 T cells compared to B6
mice [41]. We conﬁrmed that mock infected or naı ¨ve B cell / 
had decreased numbers of CD4 T cells compared to B6 mice
[41] (Figure 5). In contrast to B cell / mice, we found that the
absolute number of splenocytes, B cells, CD4 T cells, and CD8
T cells was comparable between in naı ¨ve and/or mock-
infected B6 and HELMET mice (Figure 5). Thus, the presence
of HEL-speciﬁc B cells effectively corrected deﬁciencies in T
cell numbers found in uninfected B cell /  mice.
We next evaluated the T and B cell response to cHV68
infection in HELMET mice compared to B6 and B cell / 
mice by quantifying the spleen cell populations 16 and 42 d
after infection. Consistent with previous data [36], we found
that cHV68 infection of B6 increased total splenocytes (p ¼
0.03), CD4 T cells (p ¼ 0.03), CD8 T cells (p , 0.0001), and B
cells (p ¼ 0.02) compared to uninfected mice 16 d after
Figure 3. Control of cHV68 Latency by HEL-Specific B Cells Is Not due to
Production of Cross-Reactive Antibody
(A) (Left) ELISA for cHV68-specific antibodies in serum from mock
infected and virus infected B6, HELMET, and B cell /  mice. Data are
representative of two independent experiments. (Right) Sera from mock
infected and cHV68 infected B6, HELMET, and B cell /  mice were
incubated with cHV68 and tested for their ability to neutralize cHV68
infection. Percent neutralization was normalized to results obtained
using serum from mock-infected mice of the same genotype.
(B) Beginning at day 16 post-infection, B cell /  mice were treated with
serum from mock infected or cHV68 infected B6 and HELMET mice. Ex
vivo reactivation from latency was assessed 42 d after infection.
DOI: 10.1371/journal.ppat.0020058.g003
Figure 4. HEL-Specific B Cells Restore Acute Phase cHV68 Replication to
the B Cell /  Background
Splenic viral titer measured at days 4 and 9 after cHV68 infection. Solid
lines represent the mean viral titer. Dotted lines represent the limit of
detection of the assay. Each symbol represents the viral titer in a single
mouse. Data were pooled from two independent experiments.
DOI: 10.1371/journal.ppat.0020058.g004
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Virus Non-Specific B Cells Limit Latencyinfection. B cell /  mice did not show increased total
splenocytes (p ¼ 0.37) or CD4 T cells (p . 0.05). Although
therewereslightincreasesinCD8Tcells(p¼0.005)inBcell / 
mice, the number was signiﬁcantly reduced in comparison to
the number of CD8 T cells in B6 mice 16 d after infection (p¼
0.0036). At 16 d after infection the presence of HEL-speciﬁc B
cells normalized total splenocyte numbers (p¼0.78) and CD4
(p¼0.91), and CD8 T cell numbers (p¼0.81) to levels observed
in B6 mice (Figure 5). Taking these data together, HEL-
speciﬁc B cells restored defects in cell numbers observed in
infected B cell /  mice 16 d after infection. We did not
identify all of the types of cells present in the spleens of the
different mice used here, and thus it is possible that the
presence of B cells alters the number of cells other than CD4
and CD8 T cells. The B cell response to infection observed in
B6 mice was not fully restored by the presence of HEL-
speciﬁc B cells (Figure 5). In addition, HEL-speciﬁc B cells did
not restore CD4 or CD8 responses to the level seen in B6 mice
42 d after infection. Thus, HEL-speciﬁc B cells can normalize
splenic lymphocyte numbers in uninfected mice early after
infection with cHV68, but HEL-speciﬁc B cells do not replace
all normal B cell functions.
HEL-Specific B Cells Are Activated during Early cHV68
Latency
The normalization of T cell proliferative responses early
after infection in the presence of HEL-speciﬁc B cells raised
the question of whether HEL-speciﬁc B cells are activated in
response to infection. To address this we used ﬂow cytometry
to determine the percentage of activated B cells in B6 and
HELMET mice 16 d after infection (Figure 6). Compared to
mock-infected controls, we found that the percentage of B
cells that expressed CD69 increased 2-fold in both B6 (p ¼
0.01) and HELMET mice (p ¼ 0.002) (Figure 6A) compared to
mock infected mice. Further histological examination anal-
ysis showed that germinal center-like structures formed in
HELMET and B6 mice after cHV68 infection (unpublished
data). Thus, HEL-speciﬁc B cells can be activated during
cHV68 infection independent of a virus antigen-speciﬁc BCR
or antiviral antibody.
We questioned whether this activation might be explained
by direct infection of HEL-speciﬁc B cells by cHV68. We
therefore determined whether HEL speciﬁc B cells carry
latent cHV68 16 d after infection. We found that approx-
imately 1/150 CD19þ cells in HELMET mice carried viral
genome compared to 1/700 total splenocytes (Figure 6B). We
entertained the possibility that our puriﬁcation procedure
non-speciﬁcally enriched for viral genome bearing cells, but
found that ,1:10,000 CD8 T cells puriﬁed in parallel, carried
viral genome (unpublished data). As an additional control we
determined the frequency of viral genome bearing cells in
CD19-depleted splenocytes. We found that only 1:4,400
CD19-depleted splenocytes carried viral genome. By multi-
plying these frequencies times the numbers of cells per spleen
from Figure 5, we determined that HEL-speciﬁc B cells
account for the majority of latently infected splenocytes in
HELMET mice (3.3310
5 viral genome bearing B compared to
3.4310
4 viral genome bearing non-B cells). These ﬁndings in
HELMET mice agree with previously reported data in B6
mice showing that B cells carry the majority of cHV68
genome 16 d after infection [17,18,42]. Interestingly, the
frequency of viral genome bearing HEL-speciﬁc B cells was
33-fold lower than the frequency of HEL-speciﬁc B cells
expressing CD69 (compare Figures 6A and 6B), indicating
that direct virus infection cannot fully explain activation of
HEL-speciﬁc B cells during cHV68 infection.
Virus Non-Specific B Cells Rescue T Cell Defects
in B Cell /  Mice
Taken together the experiments above indicate that HEL-
speciﬁc B cells play an important role in generating a full
CD4 and CD8 T cell proliferative response to cHV68
infection. Since CD4 and CD8 T cells are important for the
control of cHV68 latency [10,21,22,27], we postulated that
HEL-speciﬁc B cells could control latent cHV68 infection by
promoting protective CD4 and CD8 T cell responses. To
address this postulate, we further characterized T cell
expansion and activation in B6, HELMET, and B cell / mice
after infection.
The CD8 T cell response to cHV68 is heavily biased toward
T cells whose receptors are encoded by the Vb4 gene, and
expansion of Vb4þCD8 T cells is dependent on the presence
of B cells [43–46]. We used ﬂow cytometry to evaluate the
Vb4
þ T cell receptor (TCR)þ CD8 T cell expansion at 21 d
after infection, a time when it has been consistently observed
in wild-type mice [47] (Figure 7). Flow-cytometry revealed a
10-fold expansion of Vb4
þTCRþCD8 T cells in B6 (p¼0.0053)
and HELMET mice (p ¼ 0.016) relative to mock-infected
controls (Figure 7A). As expected, we did not detect the
Vb4
þTCRþ CD8 T cell expansion after cHV68 infection in B
cell /  mice. Thus, the B cell-dependent induction of Vb4þ
CD8 T cell responses to cHV68 does not required anti-viral
antibody or a virus antigen-speciﬁc BCR.
To further examine T cell activation, we used ﬂow
Figure 5. HEL-Specific B Cells Normalize Some but Not All Abnormalities
in Splenic Cellularity Observed in B Cell /  Mice
Splenocytes from pooled naı ¨ve or mock infected and cHV68 infected B6,
HELMET, and B cell /  mice were counted and stained with antibodies
against CD8, CD4, and CD19. The splenocyte numbers were the same in
naı ¨ve and mock-infected mice, and data from mock infected and naı ¨ve
mice were pooled. Numbers represent number of cells/spleen310
6. The
data are pooled from two to six independent experiments evaluating
three to five mice per experiment.
DOI: 10.1371/journal.ppat.0020058.g005
PLoS Pathogens | www.plospathogens.org June 2006 | Volume 2 | Issue 6 | e58 0582
Virus Non-Specific B Cells Limit Latencycytometry to assess the number of CD8 and CD4 T cells that
produce IFNc. Chronic activation of CD8 T cells has been
reported during long term cHV68 infection [48–50]. We
measured the number of T cells that produce IFNc 16 d after
infection based on studies showing that day 16 falls within the
peak of T cell activation during cHV68 infection [50] and that
IFNc is important for the control of cHV68 latency [10,24].
Compared to mock infection, cHV68 at day 16 induced a 10-
fold expansion of CD8 T cells that produced IFNc in B6 (p ¼
0.0027) and HELMET mice (p ¼ 0.01) while no signiﬁcant
expansion was observed in B cell /  mice (Figure 7B).
Additionally, cHV68 infection induced a signiﬁcant expan-
sion of CD8 T cells that expressed CD69 in B6 and HELMET
mice while no signiﬁcant expansion was found in B cell / 
mice (unpublished data). Similar studies of CD4 T cells
revealed a 6-fold expansion of IFNc producing CD4 T cells in
B6 mice (p¼0.002) and in HELMET mice (p¼0.006), but not
in B cell /  mice (Figure 7C). Together these data show that
the presence of HEL-speciﬁc B cells allows the induction of
an activated population of CD8 and CD4 T cells in cHV68
infected mice.
HELMET Mice Use Both CD4 T Cell- and CD8 T Cell-
Dependent Mechanisms to Limit cHV68 Latent Infection
We questioned whether the observed differences between
HELMET and B cell / mice in T cell numbers and activation
were functionally relevant to the control of latency. We
reasoned that activated T cells present in HELMET mice and
wild-type mice but not B cell / mice might contribute to the
control of latent cHV68 infection observed in B6 and
HELMET mice. To investigate this, we determined the effect
of T cell depletion on latency in B cell / and HELMET mice
(Figure 8).
Treatment with isotype control had some effect on levels of
peritoneal cell latency in both B cell /  and HELMET mice
(compare Figures 2A and 8A). We therefore considered the
levels of latency observed in isotype control antibody treated
mice as the proper control for treatment with T cell depleting
antibodies. CD4-depletion of B cell / mice had a small effect
on latency in peritoneal cells relative to isotype-control
treated mice (Figure 8A), increasing the frequency of
reactivating peritoneal cells 3-fold (p , 0.0001) in both
HELMET mice and B cell /  mice. CD4-depletion had no
effect on the frequency of viral genome bearing peritoneal
Figure 6. HEL-Specific B Cells Are Activated during cHV68 Infection and Are Infected by cHV68
(A) Splenocytes from mock infected and cHV68 infected B6 and HELMET mice were stained with antibodies specific for CD19 and CD69 16 d after
infection. Shown are the percentages of splenic CD19
þ cells that express CD69 (left). Shown are representative dot plots (right).
(B) Frequency splenic HEL-specific B cells that carry viral genome 16 d post infection (left). Shown is a representative histogram of the purity of the B cell
population after purification (right). These data are representative of two independent experiments using five mice per experiment.
DOI: 10.1371/journal.ppat.0020058.g006
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isotype control treated mice. Thus, CD4-depletion increased
the efﬁciency with which peritoneal cells reactivate from
latency.
We observed that CD4-depletion had no effect on latency in
splenocytes from B cell / mice (Figure 8A and 8B). However,
we observed a ﬁve-fold increase in reactivating HELMET
splenocytes upon CD4-depletion (p ,0.0001, Figure 8A). CD4-
depletion also increased the frequency of splenocytes carrying
viral genome more than 6-fold in HELMET mice (p , 0.0001,
Figure 8B). Therefore, the increase in reactivation was
partially due to an increase in the frequency of viral
genome-bearing splenocytes. We interpreted these data to
mean that CD4 T cells are important for the control of latent
cHV68 infection in HELMET mice.
As previously shown [29], CD8 T cell depletion of B cell / 
mice had no effect on the frequency of peritoneal cells that
reactivated ex vivo or the frequency of viral genome-bearing
peritoneal cells compared to mice treated with isotype-
control antibodies (Figures 8A and 8B). Depletion of CD8 T
cells from HELMET mice resulted in a 15-fold increase in the
frequency peritoneal cells that reactivated from latency
compared to isotype-control treated groups (p , 0.0001,
Figure 8A). This increase in reactivation was largely due to an
increase in the frequency of cells harboring viral genome
because 12-fold more peritoneal cells carried viral genome in
CD8 T cell-depleted HELMET mice compared to isotype
control treated HELMET mice (p , 0.0001, compare Figures
8A and 8B). Thus, CD8 T cells are important for controlling
latency in peritoneal cells from HELMET mice.
Similar to the results obtained from peritoneal cells, CD8-
depletion of B cell / mice had no effect on the frequency of
splenocytes reactivating ex vivo or the frequency of viral
genome-bearing splenocytes compared to isotype-control
treated mice (Figures 8A and 8B). Administration of isotype
control antibodies had no effect on splenic latency (compare
Figures 2A and 8A). However, the frequency of splenocytes
reactivating ex vivo in CD8 T cell depleted-HELMET mice was
conservatively estimated to be at least 3-fold greater than in
isotype control treated HELMET mice (p , 0.0001, Figure 8A).
Furthermore, CD8-depletion led to a 5-fold increase in the
frequency of splenocytes carrying viral genome compared to
isotype control treated HELMET mice (p , 0.0001 Figure 8B).
Together these data indicate that CD4 and CD8 T cell
dependent mechanisms control cHV68 latency in HELMET
mice, but not in B cell /  mice.
Virus Non-Specific B Cells Present Virally Encoded Antigen
to CD8 T Cells
We hypothesized that antigen presentation by B cells could
provide one explanation for the observed differences in CD8
T cell activation and function between HELMET and B cell / 
mice. To test this hypothesis, antigen presentation assays
were performed using the response of T cell receptor
transgenic T cells speciﬁc for the SIINFEKL epitope of
ovalbumin (OVA, OT1 T cells, Figure 9). Puriﬁed splenic B
cells from HELMET mice were infected in vitro with either
cHV68.OVA or cHV68.LacZ and subsequently cultured with
CFSE labeled OT1 CD8 T cells. We quantitatively measured
the ability of infected B cells to induce antigen-speciﬁc OT1
T cell proliferation. cHV68.OVA infected B cells were able to
induce about 10-fold more OT1 T cell proliferation than
cHV68.LacZ infected B cells (p ¼ 0.03, Figure 9A). We
additionally found that antigen presentation was dependent
on the number of antigen presenting cells (APCs) (unpub-
lished data). To determine whether virus replication was
required for antigen presentation, we incubated B cells with
UV-inactivated cHV68.OVA. Incubation with UV-inactivated
cHV68.OVA did not induce OT1 proliferation beyond levels
observed with cHV68.LacZ infection (Figure 9A). Therefore,
effective antigen presentation required virus replication.
Although the fractionated B cell population was .98%
pure across multiple experiments (Figure 9B) and we
depleted CD11b/cþ cells prior to B cell puriﬁcation, we
wanted to exclude the possibility that the , 2% contaminat-
Figure 7. Virus Non-Specific B Cells Restore CD8 T Cell Defects Found in
B Cell /  Mice
Splenocytes from mock infected and cHV68 infected B6, HELMET, and B
cell / mice at day 21 (A) or day 16 (B and C) were counted and stained
with antibodies specific for CD8 and TCR Vb4 (A) or CD8, CD4, and IFNc
(B and C). Shown are the numbers of CD8 T cells/spleen that are TCR
Vb4
þ (A) and the numbers of CD8 and CD4 T cells/spleen that produce
IFNc upon restimulation with PMA/ionomycin (B and C). These data were
pooled from two to three independent experiments using three to five
mice per experiment.
DOI: 10.1371/journal.ppat.0020058.g007
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4 cells) accounted for the observed antigen
presentation. To address this issue, antigen presentation
assays were performed using puriﬁed CD11b/cþcells in place
of B cells. While puriﬁed CD11b/cþ cells were able to elicit
OT1 proliferation at higher numbers (unpublished data), , 1
3 10
4 puriﬁed CD11b/cþ cells were unable to induce
signiﬁcant OT1 proliferation (Figure 9B), indicating that
contaminating CD11b/cþ cells in puriﬁed B cell preparations
did not explain antigen presentation by infected B cells.
Taking these data together, we conclude that B cells present
virally encoded antigen to CD8 T cells.
Discussion
We show here that B cells can have a signiﬁcant role in the
control of chronic c-herpesvirus infection even when they do
not produce antiviral antibody and do not express a virus
antigen-speciﬁc B cell receptor. The presence of virus-
antigen non-speciﬁc B cells normalized defective CD4 and
CD8 T cell responses observed in B cell / mice, generating T
cells sufﬁcient for the control of latent infection. Further-
more, B cell activation during c-herpesvirus infection occurs
independent of virus antigen-speciﬁc BCR expression, a
phenomenon that is not explained by latent infection of
proliferating B cells. Identiﬁcation of physiologically impor-
tant effects of virus antigen non-speciﬁc B cells on virus
infection suggests that exploitation of this property of B cells
may allow enhanced vaccine responses to chronic virus
infection. Identiﬁcation of molecular mechanisms responsi-
ble for these antibody- and BCR-independent effects on virus
infection, and for B cell activation during virus infection in
the absence of cognate antigen, may provide fundamental
insights into B cell biology and immune physiology.
Viral Antigen Non-Specific B Cells Can Control Chronic
cHV68 Infection
Since B cell /  mice lack B cells as well as antiviral
antibody, it was unclear whether phenotypes observed in
these mice such as increased cHV68 latency and increased
persistent cHV68 replication are due to the lack of B cells, the
lack of antiviral antibody, or both [7,11,14,31]. Previous
reports found that a signiﬁcant portion of the polyclonal
antibody response that occurs after cHV68 infection is not
speciﬁc to cHV68 [25,50,51], suggesting that virus antigen
non-speciﬁc B cell responses are induced by cHV68 infection.
The physiologic importance of these responses was not clear,
but provided an impetus for development of the HELMET
mouse model for analysis of virus antigen non-speciﬁc B cells
during cHV68 infection.
We conclude here that B cells can control both the number
Figure 8. CD8 T Cells Induced by the Presence of HEL-Specific B Cells Are Essential for Control of cHV68 Latency
(A) Effects of CD8- and CD4-depletion on the frequency of cells reactivating ex vivo from latency in peritoneal cells (left two graphs) and splenocytes
(right two graphs) 42 d after infection in HELMET and B cell /  mice.
(B) Effects of CD8- and CD4-depletion on the frequency of cells carrying viral genome in peritoneal cells and splenocytes 42 d after infection. These data
were pooled from two to three independent experiments using three to five mice per experiment.
DOI: 10.1371/journal.ppat.0020058.g008
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cells reactivate from latency without producing antibody or
being activated by a virus-antigen speciﬁc BCR. The lack of a
complete cellular and molecular deﬁnition of cHV68 latency
led us to measure latency using the simple parameters of the
number and reactivation phenotype of the total latent cell
pool. Thus, these studies demonstrate a fundamentally
important function of antigen non-speciﬁc B cells on the
overall level of latency, but do not address the role of B cells
in the regulation of latency in individual cell compartments
or at the molecular level.
Our conclusion that virus non-speciﬁc B cells can control
latent cHV68 infection rests in part on our data showing that
HEL-speciﬁc antibody does not bind cHV68 speciﬁcally as
measured by neutralization assays or ELISA. However, since
not all physiologically important activities of antibody are
recapitulated in in vitro assays [52–54], we also performed
passive transfer experiments to test for the presence of serum
components that would control cHV68 infection. Despite the
capacity of immune serum from normal mice to control
infection in B cell / mice, serum from HELMET mice had no
effect on latent infection. These data conclusively show that
production of virus-speciﬁc antibody is not required in order
for B cells to have profound effects on chronic herpesvirus
infection.
Antibody-Dependent Effects of B Cells on cHV68 Infection
While we show here that not all effects of B cells on chronic
cHV68 infection require antiviral antibody production,
previously published data and data presented here make it
clear that antigen speciﬁc B cell responses play an important
role in control of cHV68 infection and the normal immune
response to cHV68 infection. Passive transfer of polyclonal
antibody or antibody speciﬁc for lytic cycle viral antigens
signiﬁcantly decreases acute and latent cHV68 infection
[25,26,55]. Furthermore, passive transfer of immune serum
prior to infection can signiﬁcantly limit latent infection [56].
Antibody speciﬁc for cHV68 can neutralize virus infectivity
(this study and [25,50]). Together these data convincingly
show that speciﬁc antibody can limit cHV68 infection.
In addition to studies directly showing that antibody
speciﬁc for cHV68 can control cHV68 infection, data from
this study shows that HEL-speciﬁc B cells fail to fully
complement all abnormalities observed in cHV68 infected
B cell /  mice. For example, the presence of HEL-speciﬁc B
cells failed to reconstitute abnormal splenic T cell responses
in B cell / mice observed 42 d after cHV68 infection (Figure
Figure 9. Virus Non-Specific B Cells Present cHV68-Encoded Ag to CD8 T Cells
(A) Antigen presentation by HEL-specific B cells infected with cHV68.OVA, cHV68.LacZ, or UV-inactivated cHV68.OVA. Purified B cells were incubated
with CFSE labeled OT1 T cells to determine their ability to present antigen. Antigen presentation was measured by the ability of APCs to induce
proliferation in OT1 T cells, as shown by dilution of CFSE after cell division. Shown are representative dot plots from flow cytometry experiments with
percentages noted in the quadrants. Plots were gated on TCR Va2
þ cells.
(B) Contamination of purified B cells with CD11b/c
þ cells cannot account antigen presentation (left panel). Purity of fractionated CD19
þ cells (right
panel). These data are representative of two to six independent experiments using three to five mice per experiment.
DOI: 10.1371/journal.ppat.0020058.g009
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cells. This may reﬂect a need for either antibody or normal B
cell differentiation driven by antigen speciﬁc BCR stimula-
tion in maintenance of T cell responses during chronic
cHV68 infection. Furthermore, cHV68 establishes latency in
a memory B cell compartment [15–18], further suggesting
that normal B cell differentiation is important for aspects of
cHV68 pathogenesis and latency. All of these data support
the concept that antigen speciﬁc B cell responses are
important during cHV68 infection both by provision of
immune antibody and via roles of normal B cell differ-
entiation in viral infection.
Mechanisms by Which HEL-Specific B Cells Contribute to
Control of Latent Infection
There are multiple explanations for how HEL-speciﬁc B
cells might control latency, but we focused our attention on
the possibility that the mechanism of control of latency in
HELMET mice involved B cell dependent T cell responses.
Other groups have found that CD8 T cell responses to several
pathogens including lymphocytic choriomeningitis virus [39]
and Listeria monocytogenes [38] are abnormal in B cell /  mice.
We therefore addressed two points: (i) whether T cell
responses to cHV68 in B cell /  mice are abnormal during
chronic cHV68 infection, and if so (ii) whether HEL-speciﬁc B
cells are able to normalize T cell responses. We conﬁrmed
prior reports that the expansion of Vb4þCD8 T cells induced
by cHV68 infection is compromised in B cell /  mice
[43,44,46,57]. While the physiologic role of these Vb4
þ CD8 T
cells has not been demonstrated [58], their expansion provides
one measure of CD8 T cell proliferative responses to cHV68
infection. Abnormal Vb4 biased CD8 responses observed in B
cell /  mice were restored by the presence of HEL-speciﬁc B
cells. Several investigators have observed chronic activation of
T cells during cHV68 infection [48,49]. We found that both
CD4 and CD8 T cells were activated in cHV68 infected B6 and
HELMET mice, but not in B cell / mice.
These results, together with the demonstration that CD4
and CD8 T cells are critical for control of latent cHV68
infection [10,21,22,27], led us to question whether the
correlation between T cell expansion and activation and
control of cHV68 latency in HELMET mice was physiologi-
cally meaningful. Similar to previous reports [29], CD8 T cell
depletion had no effect on latent infection in B cell /  mice.
However, CD4 T cell depletions l i g h t l yi n c r e a s e dt h e
frequency of reactivating peritoneal cells in B cell /  mice.
Depletion of either T cell subset increased latency in HELMET
mice. We interpreted these data to mean that CD4 and CD8 T
cells were functionally relevant to the control of cHV68
latency in HELMET mice. Thus, the presence of HEL-speciﬁc
B cells resulted in expansion and activation of CD4 and CD8 T
cells that are required for control of cHV68 infection.
Since B cells are the major reservoir of cHV68 latency in
the spleen of normal mice [18,42,58], the latency observed in
B cell /  mice resides in non-B cells. HEL-speciﬁc B cells
decreased splenic latency overall, despite being themselves
latently infected (Figures 2A and 2B). Thus, the presence of
virus antigen non-speciﬁc B cells is associated with signiﬁcant
decreases in splenic latency in non-B cells. Our data do not
directly address whether B cell-dependent T cells control
latency in B cells. Additionally, while we showed that HEL-
speciﬁc B cell control viral latency in splenocytes and
peritoneal cells, our data do not address whether this effect
is direct or via control of the persistent replication in the
lung or aorta that have been observed in B cell /  mice [7,
17,59]. As the level of latency in B cell /  mice is dependent
on ongoing replication of cHV68 [25], it is possible that T
cells control latency by controlling persistent replication at
sites other than the spleen or peritoneum.
How Do HEL-Specific B Cells Promote Normal T Cell
Responses?
Several groups have shown that antigen non-speciﬁc B cells
can take up and present LCMV-derived peptides [60] and
HEL-derived peptides [61] to CD4 T cells. In addition, cHV68
infected B cells can present a ligand to CD8 T cells bearing
Vb4 with consequent activation of the Vb4
þ T cells [46,57].
These data, together with the demonstration that HEL-
speciﬁc B cells can be infected by cHV68, suggest the
possibility that HEL-speciﬁc B cells may function as antigen
presenting cells. Our data further support this hypothesis by
demonstrating that HEL-speciﬁc B cells can present virally
encoded antigen to CD8 T cells.
An alternative mechanism by which HEL-speciﬁc B cells
might contribute to normalized T cell responses is via
restoration of abnormalities in splenic architecture and
chemokine environment observed in B cell /  mice [41].
Intact splenic architecture is critical for the control of LCMV
[62]. In this regard it is important to note that HEL-speciﬁc B
cells restored some of the abnormalities in splenic cellularity
observed in uninfected and infected B cell /  mice. cHV68
infection of LTa / mice, which lack lymph nodes and have a
disrupted splenic architecture [63], results in the eventual
control of latent infection [64]. These data imply that,
although intact splenic architecture is required for the
control of some viral infections, it might not be an absolute
requirement for controlling cHV68 latency. Data presented
here do not rule out the possibility that intact splenic
architecture in HELMET mice is important for T cell-
mediated control of cHV68 latency.
Activation of B Cells during c-Herpesvirus Infection
During EBV infection, viral genes expressed in latently
infected B lymphocytes [4] drive B cell expansion. In addition
to proliferating, EBV transformed B cells express surface
phenotypes consistent with those seen during antigen
activation [65]. Studies of B cell activation during cHV68
infection have been limited to date. A component of the
expansion of B cells in vivo during cHV68 is dependent on
CD4 T cells [66]. However, exposure of splenocytes to cHV68
infection in culture results in a CD4 T cell independent
expansion and activation of B cells to express CD69 [66,67].
The requirement for virus infection and BCR speciﬁcity in
those studies was not established. However, data presented
here argues that B cells can be activated in vivo independent
of either antibody or a cHV68-speciﬁc BCR and that this is
not explained by latent virus infection as might have been
predicted based on studies with EBV.
It is notable that despite expressing CD69, HEL-speciﬁc B
cells did not signiﬁcantly proliferate during cHV68 infection.
One explanation for this is that by ﬁxing BCR expression at
the IgM/IgD stage via transgenesis, we have prevented a
physiologically important proliferative response that re-
quired cognate antigen-speciﬁc BCR engagement. Lastly, it
may be that antibody produced by virus-speciﬁc B cells is
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retaining and sequestering antigen.
Implications of these Findings for Understanding of
Immune Control of Chronic Viral Infection
It is not clear how general our ﬁnding that antigen non-
speciﬁc B cells can inﬂuence anti-viral responses will be. It is
possible, for example, that the tropism of cHV68 for B cells
during both acute and chronic infection results in a
fundamental role for antigen-non-speciﬁc B cells during this
infection that will not be present in infections by other
pathogens. However, several other studies have found a lack
of correlation between anti-viral antibody effects and B cell
effects on viral infection [39,68,69]. Together with studies
presented here, these data suggest that virus antigen non-
speciﬁc B cells may play a generally important role in the
control of virus infection.
Materials and Methods
Mice, infections, cells, and tissue harvests. HELMET mice were
bred and maintained at Washington University School of Medicine,
St. Louis, Missouri, United States, in accordance with all federal and
University policies. B6 mice were purchased from The Jackson
Laboratory, Bar Harbor, Maine, United States. Unless otherwise
stated, mice were age and sex matched and infected at 7–12 wk of age
with 1310
6 plaque forming units (PFU) of cHV68 by intraperitoneal
injection (IP) in 500 ll complete DMEM [13]. Peritoneal cells,
splenocytes, and lymph node cells were harvested and processed as
described from groups of ﬁve mice per experiment in two to six
independent experiments [36]. Crossing MD4 transgenic mice [34] on
to the B6.129S2-Igh-6
tm1Cgn (also referred to as lMT, B cell / )
background generated HELMET mice and B cell /  littermate
controls used in these studies. The presence of HEL-speciﬁc B cells
was conﬁrmed by ﬂow cytometric analysis of peripheral blood using
allotype-speciﬁc antibodies to IgM
a (DS-1, Pharmingen, San Jose,
California, United States).
Viruses, tissue culture, neutralization, and plaque assays. cHV68
clone WUMS (ATCC VR1465) was passaged, grown and titered in NIH
3T12 cells or BALB/c or C57Bl/6 (B6) murine embryonic ﬁbroblasts
(MEFs) as described [13]. cHV68.OVA and cHV68.LacZ were
generated and handled as previously described [28]. Neutralization
and plaque assays were performed as previously described [25].
Latency assays. The frequency of cells reactivating from latency ex
vivo was determined using a limiting dilution reactivation assay as
previously described [11]. Brieﬂy, we performed serial 2-fold dilutions
of harvested cells (24 wells per dilution starting at 1 3 10
5 cells per
well for splenocytes and 4 3 10
4 cells per well for peritoneal cells).
These cells were plated onto permissive mouse embryonic ﬁbroblast
monolayers for 21 d and then scored for cytopathic effect due to
reactivating virus [11]. Preformed virus in tissues was detected by
plating parallel cell samples that had been subjected to mechanical
disruption using a procedure that does not signiﬁcantly inactivate
preformed virus [36]. Samples reported here did not contain
detectable persistently replicating virus. The frequency of cells
harboring the cHV68 genome was determined in serial dilutions of
latently infected cells by a limiting dilution nested PCR assay that
ampliﬁes cHV68 gene 50 or gene 72 sequences with single copy
sensitivity [11]. Ten PCR reactions were analyzed for each of six-cell
dilutions per sample per experiment. There were no false-positive
reactions in assays reported here, and all assays demonstrated
approximately one-copy sensitivity for plasmid DNA, with control
reactions containing 10, 1, or 0.1 copies of plasmid DNA positive in
87%, 37%, and 4% of all reactions.
In vivo depletion of lymphocyte subsets and lymphocyte puriﬁca-
tion. Monoclonal antibodies (mAbs) speciﬁc to CD8b, H35, [21] were
used to deplete latently infected mice of CD8 T cells. Beginning 28 d
after cHV68 infection, 1 mg of lymphocyte-depleting antibody or an
isotype-matched control antibody, SFR3-DR5, IgG2b, ATCC HB-151,
[70] was administered to each mouse by IP injection. mAb treatment
was repeated every fourth day. The efﬁcacy of depletion was
monitored using ﬂow cytometric analysis of splenocytes using anti-
mouse CD8a. The efﬁcacy of depletion was .95% in B cell /  mice
and .90% in HELMET mice. CD19-postive B cells and CD8
þ T cells
were fractionated to .99% purity via magnetic beads (Miltenyi
Biotec, Auburn, California, United States) according to the manu-
facturer’s directions for limiting dilution PCR assays.
For antigen presentation assays, APCs were isolated as previously
described [71]. First, cells expressing CD11b and CD11c were isolated
simultaneously using CD11b and CD11c microbeads (CD11b/c subset)
(Miltenyi). CD19
þ cells were subsequently isolated from the CD11b/c-
depleted ﬂow through. More than 84% of cells within the CD11b/c
subset expressed CD11b, CD11c, or both CD11b and CD11c. In this
population, about 10% of cells expressed both CD11b and CD19 and
6% expressed CD19 alone. Cells in the CD19
þ subset were .98%
CD19
þ. We did not detect any CD11c
þ cells in the CD19
þ fraction,
however 4% of the CD19
þ cells were also CD11b
þ. CD8 T cells were
isolated from OT1 or OT1/RAG mice using magnetic beads according
to the manufacturer’s instructions (Miltenyi). CD8 T cells were then
stained with CFSE using the Cell Tracee CFSE proliferation kit
according to the manufacturer’s instructions (Molecular Probes,
Eugene, Oregon, United States).
Serum harvest, passive transfer, and ELISA. Serum was collected
from B6, HELMET, and B cell / mice 42 d after cHV68 (immune) or
mock-virus stock (control) inoculation. Passive transfers were
performed as previously described [25]. ELISAs were performed as
previously described using paraformaldehyde ﬁxed viral antigen and
goat anti-mouse IgG (HþL) (Jackson ImmunoResearch, West Grove,
Pennsylvania, United States) [25].
Antibodies and ﬂow cytometry. The following antibodies and
isotype-matched controls were purchased from BD Pharmingen (San
Jose, California, United States): anti-CD4-FITC (RM4-5), anti-CD19-
APC (1D3), anti-CD69-PE (H1.2F3), and unlabeled/puriﬁed anti-CD40
(HM40-3). Anti-CD8-TC (CT-CD8a) and anti-Vb4-PE (CTVB4), anti-
Va2-APC (B20.1), and isotype-matched controls were purchased from
Caltag (Burlingame, California, United States). Single-cell suspen-
sions were incubated with Fc-block (2.4G2) and then stained for cell
surface markers in 96-well round-bottom plates prior to analysis
using a FACSCalibur cytometer BD Biosciences Pharmingen, and FCS
Express, version 2 (De Novo software, Toronto, Ontario, Canada). For
intracellular staining, cells were activated with 20ng/ml PMA plus1lM
ionomycin for 4–6 h in the presence of GolgiPlug from the Cytoﬁx/
Cytoperm kit from BD Pharmingen. After staining the cells for
surface markers, cells were ﬁxed and permeabilized using the Cytoﬁx/
Cytoperm kit according to the manufacturer’s instructions. Next, the
cells were stained with antibodies speciﬁc to IFNc, washed and
resuspended in FACS buffer prior to analysis.
Antigen presentation assays. CD19
þ and CD11b/c
þ subsets were
incubated with either cHV68.OVA or cHV68.LacZ [72] at a multi-
plicity of infection (MOI) of 10 for 1 h (positive and negative controls
using 1nM SIINFEKL and media alone were also performed in each
experiment). APCs were then washed and incubated with 2.5 3 10
5
CFSE-labeled OT1 T cells in U-bottom 96-well plates with 200 llo f
complete RPMI media with 1:3,500 dilution of anti-CD40 mAb. 4 d
later, ﬂow cytometry was performed to determine the percentage of
proliferating T cells.
Statistical methods. All data were analyzed using GraphPad Prism
software (GraphPad Software, San Diego, California, United States).
Frequencies were obtained from the cell number at which 63% of the
wells scored positive for either reactivating virus or the presence of
viral genome based on Poisson distribution. Data were subjected to
nonlinear regression analysis to obtain single-cell frequency for each
limiting dilution analysis. The curves were statistically analyzed by
unpaired t test. All differences not speciﬁcally stated to be signiﬁcant
were insigniﬁcant (p . 0.05). Acute virus titer data were analyzed with
the nonparametric Mann-Whitney test. Data from experiments
analyzed by ﬂow cytometry were subjected to unpaired t tests. Except
where noted, data shown are the mean of two to six independent
experiments 6 SEM.
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